For research use only. This article describes a forthcoming FDA advisory-committee meeting and the section 503A regulatory framework that meeting addresses. Nothing here is legal advice; nothing here recommends any particular position on whether the substances under review should or should not appear on the 503A Bulks List. Optides supplies research-grade peptides for in-vitro laboratory work only — not for human or animal consumption — and the regulatory matters discussed below govern a separate human-use compounding channel. For full context, see our research-use disclaimer.
FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23 and 24, 2026, to discuss whether seven research peptides should be added to the section 503A Bulks List. The agenda: BPC-157, KPV, TB-500, and MOTS-c on July 23; Emideltide, Semax, and Epitalon on July 24. What follows explains what the 503A Bulks List actually is, what's on the agenda in plain terms, the three nomination categories used during evaluation, the PCAC's advisory role versus FDA's final-decision authority, and what the outcomes mean — and don't mean — for research-grade peptide supply.
What's happening on July 23-24, 2026
The PCAC is the federal advisory committee that recommends to FDA which bulk drug substances should appear on the lists permitted for pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The committee's role is advisory; the agency decides. PCAC meets several times a year. What's distinctive about the July 2026 meeting is the size of the slate — the largest single batch of research-peptide nominations to come up for review in one session.
July 23 agenda
According to FDA's published meeting notice, the July 23 session will discuss BPC-157, KPV, TB-500, and MOTS-c. Each substance appears on the agenda in both free-base and acetate forms — that is, the committee will evaluate the chemistry of the parent compound and of the salt typically supplied for compounding. Nominators of each substance are invited to make short presentations supporting the nomination.
July 24 agenda
The July 24 session will discuss Emideltide, Semax, and Epitalon under the same format. The two-day structure groups peptides with broadly similar regulatory questions together; the day-to-day breakdown is a logistical choice and does not signal anything about FDA's evaluation of any individual substance.
Why this meeting matters
The 503A Bulks List is the gating document for whether a given bulk drug substance is permitted in 503A pharmacy compounding. Inclusion opens a regulated compounding channel for a substance; exclusion closes it. The July 2026 outcomes will affect every one of the seven peptides on the agenda — and the same outcomes will be cited in industry coverage of the broader research-peptide regulatory landscape for years afterward.
What section 503A and the Bulks List actually are
The framework is widely misunderstood, so the plain-language version is worth covering carefully. Section 503A of the FD&C Act exempts certain compounded drug preparations from the new-drug-approval, current-good-manufacturing-practice, and labeling requirements that otherwise apply under federal law. The exemption is not unconditional — it applies only when the bulk drug substance used in the preparation appears on one of three lists: the United States Pharmacopeia or National Formulary, an approved drug application list, or the FDA-published 503A Bulks List. FDA's guidance for industry walks through the structure in detail.
The Bulks List versus the safety-risk list
Two FDA-published lists are commonly conflated. The 503A Bulks List is a positive list — substances on it are permitted in 503A compounding. The "Certain Bulk Drug Substances That May Present Significant Safety Risks" list is a negative list — substances on it cannot be used in compounded preparations regardless of any other consideration. A substance can be reviewed and rejected from the Bulks List without ending up on the safety-risk list; the two outcomes are distinct.
How a substance gets onto the Bulks List
The path runs through a public-nomination process. Anyone — a compounding pharmacy, a trade group, an academic researcher — can nominate a substance. FDA then evaluates the nomination, the historical-use record, the available safety and efficacy data, and any public comments received. The PCAC reviews FDA's evaluation alongside the original nomination and provides a recommendation. FDA makes the final placement decision and publishes it in the Federal Register and on FDA's website.
The peptides under review in July 2026
Each of the seven peptides on the July 2026 agenda is a chemically well-defined research-grade compound with an established place in the in-vitro and animal-model literature. The list below summarizes each compound at the level of "what is it"; deeper structural and pharmacology coverage lives in the linked references.
BPC-157
BPC-157 (Body Protection Compound-157) is a 15-residue synthetic peptide derived from a fragment of a protein found in human gastric juice. It is on the July 23 agenda in both free-base and acetate forms. For the structural details and the in-vitro literature on BPC-157, see our BPC-157 structural reference.
KPV
KPV is a tripeptide with the sequence Lys-Pro-Val, derived from the C-terminal segment of α-melanocyte-stimulating hormone (α-MSH). It has been studied in cell-culture models for its anti-inflammatory signaling effects. On the July 23 agenda.